Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental group:Celebrex capsules 200mg / time twice a day for 7 days
control group:routine treatment
Sponsors
Guangzhou Eighth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The nucleic acid of novel coronavirus 2019 was positive or the virus gene was highly homologous to the known new coronavirus. 2. The patient has fever or / and pneumonia; 3. Aged >=18 years old.
Exclusion criteria
Exclusion criteria: 1. Have a clear history of celecoxib allergy; 2. Serious nausea, vomiting, diarrhea and other clinical manifestations affect the oral or absorption of the drug; 3. Taking drugs that may interact with celecoxib at the same time; 4. Patients with serious basic diseases, such as heart disease (including history of angina pectoris or coronary heart disease of myocardial infarction, atrioventricular block), lung, kidney, liver, etc., or mental diseases that cannot be treated together; 5. History of peptic ulcer; 6. Pregnant and lactating women; 7. Suspected or confirmed that there is still a history of alcohol, drug abuse or drug abuse; 8. Participated in other drug trials in the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostaglandin E2; | — |
Countries
China
Contacts
Public ContactHong wenxin
Guangzhou Eighth People's Hospital
Outcome results
None listed